BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210921
DTEND;VALUE=DATE:20210924
DTSTAMP:20260515T211708
CREATED:20210524T114355Z
LAST-MODIFIED:20210524T114355Z
UID:30320-1632182400-1632441599@www.pharmajournalist.com
SUMMARY:4th International Cannabinoid Derived Pharmaceuticals Summit
DESCRIPTION:The Cannabinoid Derived Pharmaceuticals Summit is the world’s largest conference devoted exclusively to the production of CDPs for medical conditions using FDA/EMA approval pathways. The 2021 agenda will focus on clinical trial design and commercialization\, target biology and pharmacology\, GMP-compliant product formulation\, drug delivery\, and managing the changing regulatory environment (particularly in light of new policies from the US government administration). \n \nThe Three-day Program Spans: \n\nA brand-new section dedicated to building a robust clinical strategy will equip you with the knowledge that gave world leading cannabinoid drug developers a commercial and clinical edge in the race to approval\nAnalyzing new discoveries in cannabinoid pharmacology and ECS biology to identify new opportunities\nDiscussion of vital IP and investment topics for a comprehensive update on the health of the industry\nPreparation for post-approval through exploration of key issues relating to commercialization and supply chain management of cannabinoid medicine products and APIs\n\nThe 4th International Cannabinoid-Derived Pharmaceuticals Summit brings together drug developers working on the complex and difficult production of both plant-based and synthetic endocannabinoid system modulators. An elite panel of speakers will discuss important topics such as rigorous clinical trial data exchange\, guided discussion\, and industry networking. \nMeet face-to-face with decision makers from the likes of Greenwich Biosciences\, ACHEM\, Cannvalate\, Cannabics Pharmaceuticals\, Oxford Cannabinoid Technologies and more at the first physical cannabinoid conference of the year. \nTo know more about 4th International Cannabinoid Derived Pharmaceuticals Summit please click here.
URL:https://www.pharmajournalist.com/event/4th-international-cannabinoid-derived-pharmaceuticals-summit/
LOCATION:Aloft Boston Seaport District\, 401-403 D St\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210921
DTEND;VALUE=DATE:20210924
DTSTAMP:20260515T211708
CREATED:20210525T115351Z
LAST-MODIFIED:20210525T115440Z
UID:30335-1632182400-1632441599@www.pharmajournalist.com
SUMMARY:2nd Gene Therapy for Ophthalmic Disorders
DESCRIPTION:Returning in September as a digital event\, the 2nd Gene Therapy for Ophthalmic Disorders meeting will target the industry’s translational challenges in targeting both rare and common ophthalmic disorders including wet AMD\, dry AMD\, DME\, IRDs and more. \nDiscover novel vectors and administration routes for optimal retinal delivery with 30+ world class speakers from the likes of GenSight Biologics\, Biogen\, Gyroscope Therapeutics\, Novartis\, Horama and REGENXBIO \n \nJoin 150+ fellow industry attendees from discovery\, preclinical and clinical backgrounds\, to learn lessons in rare disorders and seize the opportunity in common ophthalmic disorders. \nThis meeting will allow you to: \n\nHear the latest data in ocular gene therapy immunogenicity and vector strategies to overcome Inflammation\nHighlight optogenetics and gene agnostic approaches from SparingVision\, GenSight Biologics and Bionic Sight\nLearn how Clearside Biomedical are progressing suprachoroidal delivery with the potential to minimize invasive surgical procedures\nDiscuss the clinical progress with different administration routes to the eye with clinical experience from REGENXBIO\nGain key vector insights from Eyevensys\, who are developing non-viral vectors to minimize immune response and increase likelihood or re-dosing\nExplore the realities of clinical trial design to meet regulatory expectations throughout a program\, with insights from Gensight Biologics\nHear pharma representatives discuss the opportunities and realities of collaborating with biotechs\, with experience from Novartis\nHear from a Luxturna patient to understand their first-hand experience of receiving the therapy\, and have an opportunity to ask them your questions\nHighlighting progress in ASOs for ophthalmic disorders for a deeper understanding of the ophthalmic landscape with data from ProQR\n\nView the event guide here for full agenda details and the expert speaker faculty.
URL:https://www.pharmajournalist.com/event/2nd-gene-therapy-for-ophthalmic-disorders/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210921
DTEND;VALUE=DATE:20210924
DTSTAMP:20260515T211708
CREATED:20210610T122026Z
LAST-MODIFIED:20210610T122340Z
UID:30508-1632182400-1632441599@www.pharmajournalist.com
SUMMARY:6th Annual PREDiCT: 3D Tissue Models Summit
DESCRIPTION:The 6th PREDiCT: 3D Tissue Models Summit is the only industry-led summit focusing on real-world application of 3D models in drug discovery and development. With 25+ experts sharing fresh case studies on 3D Tissue Models data\, how to foster technology maturation\, and lower costs to drive industrial adoption\, this is a conversation not to miss. \n \nReturning as an in-person meeting in Boston\, our 2021 program will delve further into advanced 3D organoids\, organ-on-chips\, microphysiological systems (MPS)\, and tissue engineering – from oncology to other therapeutic areas – not only in preclinical safety and toxicology models but also back to translation in clinical Ph1 for biomarkers and patient stratification for better Ph2 design. \nJoin 80+ experts on scientific and real-world application dialogues with the likes of FDA\, GSK\, Takeda\, MIT\, and many more\, sharing their journeys and lessons learned with complex in vitro models\, compared with conventional in vivo and 2D cell studies. \nTo find out more and view the 2021 speaker line-up\, download the full event guide. \nBook with confidence! – As the world begins to re-open and in-person events become a reality\, join us again in Boston for the first time in more than a year\, to learn expert insights and generate quality industry connections in a face-to-face capacity. See how we’ll ensure your safety here.
URL:https://www.pharmajournalist.com/event/6th-annual-predict-3d-tissue-models-summit/
LOCATION:The Colonnade Boston – 120 Huntington Avenue\, Boston\, MA 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210922
DTEND;VALUE=DATE:20210924
DTSTAMP:20260515T211708
CREATED:20200416T105628Z
LAST-MODIFIED:20200710T092049Z
UID:25059-1632268800-1632441599@www.pharmajournalist.com
SUMMARY:Oligonucleotide Therapeutics and Delivery Conference
DESCRIPTION:On the way to maximising the potential of oligo-based medicine \nOligonucleotide therapeutics – the emerging medicine class – are harnessing the therapeutic benefit of targeting genetic material via antisense\, mRNA\, RNAi\, saRNA and siRNA. Their market growth: CAGR of 13.7% projected to reach USD 8.2 billion by 2024 is driven by their potential to provide more efficacious and less toxic alternatives to small molecules. They bring about the ability to affect targets that have been considered “non-draggable”. Heavy investments in oligonucleotide therapeutic discovery have created an emerging market need for drug delivery technologies. \n \nSMi’s inaugural Oligonucleotide Therapeutics and Delivery conference is here to keep you updated. By bringing together leading representatives of pharmaceutical\, biotechnology and academic institutions\, the 2-day conference will provide first-hand information on the latest clinical trial candidates and a platform for exchanging ideas for tackling the biggest challenge: DELIVERY. From optimizing particle size to choosing the right nanocarrier systems\, the conference will address delivery to non-hepatocyte cells such as cancerous tissues and overview the most successful platforms. Discussions will be centered around improving targeted therapy uniting the field’s biggest players to share their opinions. \nEstablished on the success of our RNA Therapeutics series\, we look forward to welcoming you at Oligonucleotide Therapeutics and Delivery to join the conversation around maximizing the potential of oligo-based treatments. \nBenefits of attending: \n\nGain first-hand insight into oligonucleotide therapy clinical success up to date for improving development of novel agents in your pipeline\nListen to case studies presenting the latest candidates undergoing pre-clinical and clinical research\nDeepen your understanding of crucial delivery methods and available platforms for non-hepatocytic delivery\nCollaborate with members of the oligonucleotide community leading pharmaceutical\, biotechnology and academic representatives to maximise future opportunities\n\nPlus\, an interactive half day pre-conference workshop on Oligonucleotide drug discovery: Target selection\, delivery\, molecular design and lead identification. \nCHAIR FOR 2021:  \n\nNagy Habib\, Head of HBP Surgery\, Imperial College London and Co-Founder\, Head CNN of R&D and Chief Medical Officer\, Mina Therapeutics\n\nSCIENTIFIC ADVISORY BOARD 2021:\n \n\nEkkehard Leberer\, Senior Director\, Alliance Management\, Sanofi\nMark Edbrooke\, Independent Consultant\nTroels Koch\, Chief Technology Officer\, SVP Science and Technology\, Inexos Therapeutics\nSudhir Agrawal\, Founder and President\, ARNAY Sciences and Idera Pharma and Professor\, University of Massachusetts Medical School\n\nFEATURED 2021 SPEAKERS INCLUDE:  \n\nDavid Evans\, Chief Scientific Officer\, Sirnaomics\nAlexey Wolfson\, CEO\, Advirna\nStefan Vonhoff\, VP Chemistry & Manufacturing\, NOXXON Pharma\nVera Brinks\, Director Pharmaceutics\, ProQR Therapeutics\nMatthew Catley\, Research Director\, MiNa Therapeutics\nSteve Pascolo\, Founder and CEO\, Miescher Pharma\n\nWho should attend: \n\nRNA Biology/Discovery\nNovel Therapeutic Modalities\nInnovation Technologies\nC-level Scientific Executives\nFormulation and Drug Delivery\nClinical Research and Development\nCell Biology\n\nAdditional Contact Info:\nT: +44 (0)20 7827 6088\nE: hsidhu@smi-online.co.uk \nLinkedIn: @SMi Pharma\nTwitter: #SMiOligonucleotides
URL:https://www.pharmajournalist.com/event/oligonucleotide-therapeutics-and-delivery-conference/
LOCATION:Holiday Inn Kensington Forum\, London\, London\, United Kingdom
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210922
DTEND;VALUE=DATE:20210924
DTSTAMP:20260515T211708
CREATED:20200427T082728Z
LAST-MODIFIED:20200605T145115Z
UID:25298-1632268800-1632441599@www.pharmajournalist.com
SUMMARY:Aseptic Processing Conference
DESCRIPTION:SMi’s Aseptic Processing Conference\nExploring aseptic facility design and operation to implement agile contamination control strategies Conference: 22 – 23 September 2021\nLocation: Copthorne Tara Hotel\, London\, UK\nWebsite: http://www.asepticprocessing.co.uk/PJWL \nSPONSORED BY: Innerspace & Steris  \nCHAIRED BY: James Drinkwater\, Head of Aseptic Processing & Containment Special Interest Group\, PHSS and Richard Denk\, DACH Affiliate\, ISPE  \n \nThe aseptic processing industry has seen many changes during its progression towards the 21st century. With advances in innovative therapeutic manufacturing such as ATMPs\, pragmatic barrier system applications\, adaptability and modularity in fill finish\, robotics and automation\, small and agile product manufacturing\, just to name a few. In 2018\, the global aseptic processing market was valued over $56 trillion and is estimated to increase in net revenue upwards $124 trillion by 2027\, with a CAGR growth of 9.18%. \nThe industry is ever changing and with the advent of innovative therapeutics taking hold\, regulators and industry leaders are prompted to take proactive approaches to get treatments to patients faster. \nJoin us to explore novel and developing technologies that tackle the most pressing challenges and push innovation in the world of aseptic processing and sterile manufacturing.  \nEvent Hashtag: #SMiAseptic \nAt the Aseptic Processing Conference\, you will gain insight into: \nFeatured 2021 Speakers include: \n\nScott Nichols\, Microbiologist\, FDA\nSerena Ambrosini\, Sterile Manufacturing Manager\, AstraZeneca\nJim Polarine\, Senior Technical Service Manager\, Steris Corporation\nDi Morris\, Audit Manager CAG\, GSK\nStephen Yang\, Director\, Global Sterile Validation COE\, Merck\nKevin Jenkins\, Consultant\, Quality Excellence Consulting\n\n KEY HIGHLIGHTS INCLUDE FOR 2021 \n\nDiscuss the latest regulatory updates in the industry from leading regulatory bodies\nListen to global case studies in aseptic competence from companies pioneering in the pharmaceutical industry\nExplore advances in ATMP facility design that are revolutionising aseptic manufacturing\nDelve into the newest contamination control technologies from VHP disinfection to fully automated pipelines \n\nPLUS – Pre-conference workshop on… \nContamination control measures in Good Manufacturing Practice (GMP) applied to Aseptic processing \nWorkshop leaders:  James Drinkwater\, Head of Aseptic Processing and Containment Special Interest Group\, PHSS and Kevin Jenkins\, Consultant\, Quality Excellence Consulting \nView the brochure and to download visit http://www.asepticprocessing.co.uk/PJWL
URL:https://www.pharmajournalist.com/event/aseptic-processing-conference/
LOCATION:COPTHORNE TARA HOTEL\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210928
DTEND;VALUE=DATE:20211001
DTSTAMP:20260515T211708
CREATED:20210524T114659Z
LAST-MODIFIED:20210524T114953Z
UID:30324-1632787200-1633046399@www.pharmajournalist.com
SUMMARY:4th Annual Neuropsychiatric Drug Development Summit
DESCRIPTION:This last year has been a brutal reminder as to how crucial it is that we tackle the impending global mental health crisis and find a path towards successful neuropsychiatric drug development. \nWe are proud to be the industry’s definitive and unrivalled forum focused on encapsulating the recent clinical advances across this extremely arduous field. This timely meeting provides a much-needed platform for industry and academic thought leaders to: \n\nInvestigate new treatment paradigms to support schizophrenia patients with Sunovion\, Merck\, Cerevel and BioXcel\nStrive for useful biomarkers in clinical practice and explore novel electrophysiological biomarkers of synaptic plasticity in humans with Lundbeck\, Daniel Javitt and Takeda\nHear patient-centric approaches towards developing efficacious and engaging digital therapeutics with Thomas Insel\, MindMed\nDecipher the recent hype in psychedelics by evaluating new data emerging on hallucinogens with Psilera\, MAPS\, Eleusis\, ATAI and Perception Neuroscience\nDiscover the major advances in understanding neuroinflammation across CNS indications and how can we use this to help us further understand psychiatric conditions with Johnson & Johnson and Inmune Bio\n\nDon’t miss out and join over 80 of your peers at this timely event to take a step closer towards your ambitious goal of drastically improving the lives of individuals living with neuropsychiatric disorders. \nTo know more about 4th Annual Neuropsychiatric Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/4th-annual-neuropsychiatric-drug-development-summit/
LOCATION:Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210929
DTEND;VALUE=DATE:20211002
DTSTAMP:20260515T211708
CREATED:20210521T123937Z
LAST-MODIFIED:20210521T124307Z
UID:30236-1632873600-1633132799@www.pharmajournalist.com
SUMMARY:12th Annual World Bispecific Summit
DESCRIPTION:The 12th Annual World Bispecific Summit will deliver a greater scope and penetration of innovative technical content than any other meeting. This year’s re-imagined agenda will cover unique discovery\, translational\, and manufacturing challenges faced in the bispecific field. Whatever your role and interest\, you will leave the meeting with concrete methods to employ into your strategy and pipeline to convert the promise of bispecific therapeutics into a reality for patients. \n \nDiscover who the 45+ expert speakers are\, and the topics they will examine\, including how: \n\nOSE Immunotherapeutics is pioneering their unique platform BiCKI a bispecific platform optimized for the development and manufacturing of bispecific cytokine fusion proteins\nGT Biopharma and Light Chain Bioscience are showcasing the next generation of innate cell engagers for the treatment of solid tumors\nMerus\, Pfizer\, and Innate Pharma are expanding the boundaries of biotherapeutics with tri-specific and multi-specific antibodies\nGenentech\, Pfizer\, and City of Hope are discussing approaches to reduce on-target off-tumor toxicities including dosing strategies in liquid and solid tumor indications\nXencor\, Harbour Biomed\, and Harpoon Therapeutics will discuss their unique platforms and CMC strategies for scale-up and production\nIGM Biosciences and MacroGenics will evaluate biomarker strategies for bispecific candidates during clinical development\n\nTo know more about 12th Annual World Bispecific Summit please click here.
URL:https://www.pharmajournalist.com/event/12th-annual-world-bispecific-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210929
DTEND;VALUE=DATE:20211001
DTSTAMP:20260515T211708
CREATED:20210721T205309Z
LAST-MODIFIED:20210721T205309Z
UID:31026-1632873600-1633046399@www.pharmajournalist.com
SUMMARY:11th World Clinical Biomarkers & CDx Summit
DESCRIPTION:Accelerating R&D to Commercialization by Leveraging Predictive Biomarkers & Clinical Diagnostics Evidence for Best Patient Outcomes in Target Populations \nThe 11th World Clinical Biomarkers & CDx Summit returns in 2021 as the only end-to-end industry-led meeting diving deep into the science of transitioning biomarkers to the clinic\, their clinical validation and later commercialization with a CDx. \nWith over half of drugs approved by the FDA now supported by a biomarker and as new CDx collaborations are announced on an almost weekly basis\, demand for diagnostic tools enabling earlier\, more precise\, therapeutic interventions is at an all time high. Join with 650+ key stakeholders across biomarker\, translational\, clinical\, regulatory and commercial functions to tackle end-to-end challenges and deliver game-changing drug-Dx products to market. \nAcross 2 days of comprehensive content\, 65+ global expert speakers will share fresh data paired with inspiring stories from innovative partnership collaborations to help you overcome your most pressing challenges and accelerate curative medicine for heterogeneous patient populations. \nWith 3-tracks addressing the entire lifecycle of biomarker-driven drug development\, explore biomarkers and Dx movement within bioanalytical analysis\, AI/ML application\, data sharing and the regulatory and payer landscape. Covering immune-oncology\, neurodegenerative\, metabolic\, autoimmune and rare indications\, gain a diverse picture of today’s expanding personalized medicine ecosystem. \nThis is your unmissable event\, bringing you the tools\, insights and techniques to design a clinically robust biomarker and commercially competitive CDx! \nTo know more visit: https://world-cdx.com/
URL:https://www.pharmajournalist.com/event/11th-world-clinical-biomarkers-cdx-summit/
LOCATION:Digital
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211005
DTEND;VALUE=DATE:20211009
DTSTAMP:20260515T211708
CREATED:20210301T101605Z
LAST-MODIFIED:20210301T101605Z
UID:29208-1633392000-1633737599@www.pharmajournalist.com
SUMMARY:9th Annual MarketsandMarkets Biomarker and Companion Diagnostics Virtual Conference (EST TIME ZONE)
DESCRIPTION:Leveraging next gen technologies beyond conventional biomarker drug discovery \nThe emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology\, immuno-therapies\, data interpretation and unconventional design of clinical trials. \nThe 9th Annual MarketsandMarkets Biomarker and Companion Diagnostics Virtual Conference scheduled to be held from 5th – 8th October 2020 would address the gaps between early-stage biomarker development and the commercialization stage of biomarkers. \nThis conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers\, Precision Medicine and Big Data. Regarding the commercialization of biomarkers\, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to the clinical translation of biomarkers. \nEvent Website: https://events.marketsandmarkets.com/9th-annual-marketsandmarkets-biomarker-and-companion-diagnostics-virtual-conference/  \nRegistration link:  https://events.marketsandmarkets.com/9th-annual-marketsandmarkets-biomarker-and-companion-diagnostics-virtual-conference/register
URL:https://www.pharmajournalist.com/event/9th-annual-marketsandmarkets-biomarker-and-companion-diagnostics-virtual-conference-est-time-zone/
LOCATION:Virtual Event
ORGANIZER;CN="Marketsandmarkets":MAILTO:Shardul.oza@marketsandmarkets.com, events@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211005
DTEND;VALUE=DATE:20211008
DTSTAMP:20260515T211708
CREATED:20210802T091237Z
LAST-MODIFIED:20210802T091416Z
UID:31169-1633392000-1633651199@www.pharmajournalist.com
SUMMARY:2nd Annual B&T Cell-Mediated Autoimmune Disease Drug Development Summit
DESCRIPTION:The 2nd Annual B&T Cell-Mediated Autoimmune Disease Drug Development Summit is the only event uniting key B&T cell decision-makers to advance the therapeutic future of autoimmune diseases. \nJoin this community of 60+ pioneers to aid discovery\, development\, optimization and strategy for a new generation of treatment within this area of vastly unmet clinical need. \nThis cross-disciplinary program featuring keynote talks from 32+ clinical KOLs from large pharma\, biotech and academia\, will give you insight into the full therapeutic opportunity of drug candidates against various plasma\, B and T cell targets. \nUnite with other B & T cell researchers as we look to optimize therapeutic targeting of the bidirectional interactions between B and T cells\, B cell functions (autoantibody production\, antigen presentation\, T cell help & cytokine production) and autoreactive T cells contribution to autoimmune pathogenesis and disease progression. \nView our full event guide to see our complete speaker line-up\, latest agenda\, and workshop details. https://ter.li/0zk3pp \nKey Discussions you Can’t Afford to Miss: \n\nDelve into the exciting world of cell engineering and novel targets for rare autoimmune diseases and what they mean for the field with Abcuro\, Polyneuron\, Apitope\, NYSCF\, UTHSC & Cabaletta Bio\nDiscover the novel and promising candidates targeting B cell development factors and related cytokines with Eli Lilly & Co\, UCL\, Kyverna\, Immunic AG\, Nurix & GSK\nUncover the pathologies and targets for the B & T cell co-stimulatory pathways and novel mechanisms in disrupting collaboration with Artax Bio\, Cytocom\, Horizon\, AltruBio & Novartis\nExplore targets\, considerations and strategy for targeting autoantibody producing plasma cells\, organ specific and systemic diseases with UCB\, Provention Bio\, IM Therapeutics & Biogen\nOptimize application and patient outlook through combination strategies\, early detection and emerging biomarkers and look to next steps in your drug development with Oklahoma Medical Research Foundation\, Bristol-Myers Squibb & Eli Lilly & Co\n\nFind out more https://ter.li/0zk3pp
URL:https://www.pharmajournalist.com/event/2nd-annual-bt-cell-mediated-autoimmune-disease-drug-development-summit/
LOCATION:Digital Event | EST
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211006
DTEND;VALUE=DATE:20211008
DTSTAMP:20260515T211708
CREATED:20200520T093405Z
LAST-MODIFIED:20200731T100028Z
UID:25600-1633478400-1633651199@www.pharmajournalist.com
SUMMARY:SMi's 2nd Next Generation Pharmaceutical Cleanroom Conference
DESCRIPTION:SPONSORED BY: Elis Cleanroom and Innerspace\nCHAIRED BY: Matts Ramstorp\, CEO & Founder\, BioTekPro \nAddressing the Microbiological Aspects in Cleanroom Design & Engineering \nSMi Group are pleased to announce the 2nd Annual Next Generation Pharmaceutical Cleanroom Europe Conference. An event that focuses on cleanroom technology in the pharmaceutical industry\, the conference will serve to bridge that gap between the two areas while simultaneously providing a unique selling point. \nThis one-of-a-kind meeting will facilitate networking opportunities with key opinion leaders from all areas of pharmaceuticals\, biologicals\, and cleanroom industry experts to explore hot topics within cleanroom design and engineering\, best practices and regulation\, environmental and contamination control\, and pharmaceutical microbiology. \n \nIn 2025\, the global cleanroom technology market is expected to reach nearly $5 billion. Stringent regulatory standards for product approvals\, technological advancements in cleanrooms\, initiatives taken by private organisations to create awareness regarding cleanroom and growth of the healthcare sector globally are among the few factors expected to drive the market. \nThis event will look in-depth at the significant change that the cleanroom industry is going through. From the new operating practices that keep the product as sterile as possible\, to the developments in technology that are enabling this to happen. Whether through robotics\, automated disinfection\, or data driven environmental monitoring- this conference will highlight the developments that are fundamentally changing the industry. \nEvent Hashtag: #SMiCleanroom \nHIGHLIGHTS FOR 2021: \n\n UNDERSTAND the current regulatory landscape from both designer and regulator perspectives\n EXPLORE the innovations in technology that are shaping the next generation of cleanroom facilities\n DETERMINE the best approaches to cleanroom design and operation from global case studies\n GAIN insight into the latest developments in cleanroom protocol from leading industry experts\n\nFEATURED 2021 SPEAKERS INCLUDE: \n\nTim Sandle\, Head of Microbiology and Sterility Assurance\, Bio Products Laboratory Ltd\nConor Murray\, Principal\, Irish Cleanroom Society\nJoseph McCall\, Associate Director\, QA Technical Service\, ADMA Biologics\nBenoît  Ramond\, Head of Microbiology & Sterile Technology\, Sanofi\nWalid El Azab\, Senior Manager Technical Services\, STERIS\nDawn Tavalsky\, Senior Director Global Sterility Assurance\, Sanofi Pasteur\nPatrizia Muscas\, QA & Sterility Assurance\, Eli Lilly\nChristine Arbesser-Rastburg\, Director\, Head of Global Microbiology\, Takeda\n\nWHO SHOULD ATTEND: \nSenior Micro Manager\, QC Manager\, Quality Director\, Clean Room Design Managers\, Design\, Qualify and Testing – Clean Room (across the board)\, Head of Clean Room Technologies\, Head of Compounding Pharmacies\, Head of Clinical Drug Products\, Head of Clinical Medical Device \nADDED VALUE – 2 x Pre-Conference Workshops on…\nWorkshop A – 08.30 – 12.30: Applying ISO and EN Standards to Non-Viable and Viable EM in the context of the new Annex 1 guidance and a CCS in GMP Cleanrooms\nWorkshop Leader: Conor Murray\, Principal\, Irish Cleanroom Society  \nWorkshop B – 13.30 – 17.30: Cleanroom Garments – need\, function and use\nWorkshop Leader: Matts Ramstorp\, CEO & Founder\, BioTekPro \nView the brochure and to download visit www.cleanroomtechnology.co.uk/PJwl
URL:https://www.pharmajournalist.com/event/smis-2nd-next-generation-pharmaceutical-cleanroom-conference/
LOCATION:Copthorne Tara Hotel\, London\, United Kingdom
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211018
DTEND;VALUE=DATE:20211020
DTSTAMP:20260515T211708
CREATED:20190503T072628Z
LAST-MODIFIED:20210519T083857Z
UID:20546-1634515200-1634687999@www.pharmajournalist.com
SUMMARY:Wearable Injectors and Connected Devices Conference
DESCRIPTION:The latest innovations in digital health and on-body drug delivery for the pharmaceutical industry \nSMi’s 2nd annual Wearable Injectors and Connected Devices Conference will explore real world case studies of on-body device design and development for large volume delivery while engaging in the latest digital applications for wearable devices with industry case studies from pharma thought leaders. The conference will consider key developments in the wearable injectors field\, including the enhanced demand for on-body injectors and digitalised health as the pandemic highlights the need for self-administered at-home care\, managing sustainability in the field\, and opportunities for development in oncology. \n \nKey regulatory updates including guidance on MDR requirements and the impact of Brexit on data collection will be presented by regulatory experts for a comprehensive outlook of this exciting and ever-growing field\, and the importance of considering human factors in order to enhance the user experience will be presented by industry experts. \nThis two-day agenda offers you peer-to-peer networking with Global Device Development Managers\, Senior Connectivity Engineers\, Leaders in Device Data Generation\, Human Factors Directors and many more. \nWe look forward to welcoming you to the conference in October. \nFor more information and to register: www.wearable-injectors.co.uk/pjwl   \nBENEFITS OF ATTENDING: \n\nGain insight into developments in wearable devices in clinical trials and adapting to decentralised trials during the pandemic\nExplore design strategies for connectivity and digital health with sessions from Novartis and Bayer\nHear key regulatory updates from regulatory and notified bodies including TÜV SÜD\nDiscover advances in device design for large volume delivery via on-body injectors\nExplore and benchmark against industry developments through case studies and real-world examples in device development for on-body injectors\n\nPlus\, two interactive half-day workshops – Wednesday 20th October 2021 \nA: Cross company collaboration to develop digital therapeutic solutions using connected devices\nWorkshop Leader:\nDigby Harris\, Global Procurement Lead – Digital Therapeutics\, AstraZeneca \nB: Optimising Patient Engagement and Creating Novel Company Value through Digital Technologies\nWorkshop Leaders:\nAlex Gilbert\, Digital Medicine\, Huma \nEarly-Bird Rates \n\nBOOK BY JUNE 30TH TO SAVE £200\nBOOK BY AUGUST 31ST TO SAVE £100\n\nSOCIAL MEDIA HANDLES \nTwitter: @SMiPharm #SMiWearables\nLinkedIn: follow our company page – search ‘SMi Pharma’
URL:https://www.pharmajournalist.com/event/wearable-injectors-and-connected-devices-conference/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SMi Group Limited":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211019
DTEND;VALUE=DATE:20211022
DTSTAMP:20260515T211708
CREATED:20210524T113716Z
LAST-MODIFIED:20210524T113716Z
UID:30317-1634601600-1634860799@www.pharmajournalist.com
SUMMARY:2nd Annual Dry-AMD Therapeutic Development Summit
DESCRIPTION:Returning for its 2nd year as the world’s leading industry forum\, Dry-AMD Therapeutic Development establishes meaningful clinical endpoints using the latest diagnostic imaging techniques to prove therapeutic safety and efficacy in specific patient populations. \nIn the context of unprecedented Phase III progress\, and as new investigational pharmacological agents enter the clinic\, Dry-AMD Therapeutic Development will deliver a greater breadth and depth of technical content than any other meeting in this field with 3 days and 2 tracks of dedicated content. \n \nUniting large pharma\, biotech and academic KOLs with a reimagined agenda\, this year’s meeting devotes specific content to the unique discovery\, pre-clinical\, translational\, clinical development and commercialization challenges encountered within the dry-AMD space. Ensuring that whatever your role in the field\, you will leave with tangible actions to implement into your strategy and pipeline\, to translate the promise of dry AMD therapies into a reality for patients. \nJoin the 200+ expert community\, as they unite under a common goal of accelerating the approval of next generation therapies for this progressive eye disease. \nTo know more about Dry-AMD Therapeutics Summit please click here.
URL:https://www.pharmajournalist.com/event/2nd-annual-dry-amd-therapeutic-development-summit/
LOCATION:Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211025
DTEND;VALUE=DATE:20211027
DTSTAMP:20260515T211708
CREATED:20210519T082947Z
LAST-MODIFIED:20210519T082947Z
UID:30203-1635120000-1635292799@www.pharmajournalist.com
SUMMARY:Medical Wearables for Biosensors USA Conference 2021
DESCRIPTION:Exploring therapeutic applications of connected on-body devices \nThe global wearable biosensors market is a rapidly expanding industry with increasingly growing potential for applications in healthcare and technological advances. With potential in remote patient monitoring\, diagnosis and detection of disease\, biosensors and wearable devices are gaining substantial interest due to their opportunities to offer continuous and reliable physiological information allowing for better support of patient needs. \nWith that in mind\, SMi is proud to present the Designing Biosensors for Medical Wearables Conference\, taking place on the 25th – 26th October 2021 in Boston. \n \nBENEFITS OF ATTENDING: \n\nEngage in case studies from leading experts on wearable devices for remote diagnostics and patient monitoring\nExplore how industry is using on-body biosensors for a patient centric-approach to therapeutics\nDelve into the regulatory landscape of digital health and data management with regulatory body and leading expert addresses\nUncover the evolving research into smart vaccines for COVID-19 and accelerating accessibility of new wearable technologies\n\nRegister online: www.biosensors-medical-wear.com/pjwl \nPlus\, two interactive half-day workshops – Wednesday 27th October 2021 \nA: Digital Integration within Clinical Trials \nWorkshop Leaders:\nGary McNamara\, Senior Delivery Manager\, Aparito\nDaniel Lewi\, Head of Business Development\, Aparito \nB: Energy Harvesting Systems for Body-Worn Sensors \nWorkshop Leaders:\nVeena Misra\, Distinguished Professor\, Director\, NSF Center for Advanced\nSelf-Powered Systems of Integrated Sensors and Technologies (ASSIST) \nEarly-Bird Rates \n\nBOOK BY JUNE 30TH TO SAVE $200\nBOOK BY AUGUST 31ST TO SAVE $100\n\nSOCIAL MEDIA HANDLES \nTwitter: @SMiPharm #SMiBiosensors\nLinkedIn: follow our company page – search ‘SMi Pharma’
URL:https://www.pharmajournalist.com/event/medical-wearables-for-biosensors-usa-conference-2021/
LOCATION:Sheraton Boston Hotel\, Boston\, USA (Virtual Attendance Option Available)
ORGANIZER;CN="SMi Events":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211026
DTEND;VALUE=DATE:20211030
DTSTAMP:20260515T211708
CREATED:20210617T150512Z
LAST-MODIFIED:20210628T073150Z
UID:30590-1635206400-1635551999@www.pharmajournalist.com
SUMMARY:4th Targeted Protein Degradation Summit
DESCRIPTION:As the most comprehensive\, industry-focused and ‘must-attend’ event in the field\, the 4th Targeted Protein Degradation Summit returns to once again explore the latest approaches\, perspectives\, and data-drive case studies that will continue to advance PROTACs\, molecular glues\, and other degrader modalities towards clinical success. \nWith 70+ world-class speakers and over 500 senior attendees from around the globe\, join the largest community of protein degradation experts for a deep dive into clinical development progress\, lessons learnt and novel strategies to develop safe\, selective and effective PROTACs\, molecular glues\, lysosomal degradation\, autophagy-mediated degraders as well as uncovering novel degrader modalities and approaches for oncology and beyond. \nKey Highlights: \n\nEvaluate the exclusive updates of ongoing clinical trials to accelerate towards the first clinically approved therapy with insights from Kymera Therapeutics\, Arvinas\, Nurix Therapeutics & Bristol Myers Squibb\nDeep dive into the methodologies of enhancing target engagement by improving target specificity\, uncovering strategies to find novel ligases and modelling of covalency to develop next generation degraders with insights from Eli Lilly\, FogPharma\, GSK & Janssen\nReview the plethora of disease indications that are being targeted by PROTACs and molecular glues including Alzheimers\, Parkinsons\, COVID-19 and AML with insights from Bristol Myers Squibb\, Progenra & Origami Therapeutics\nExplore the different approaches to penetrating the blood brain barrier\, comparing and contrasting the discovery\, development and optimization of PROTACs and molecular glues for neurodegenerative indications with insights from C4 Therapeutics & Progenra\nOutline the core mechanisms of PROTAC resistance and the approaches to overcoming this to successfully progress through preclinical and clinical studies with insights from University of Dundee\, Ranok Therapeutics & Captor Therapeutics\n\nTo know more about 4th Targeted Protein Degradation Summit please click here.
URL:https://www.pharmajournalist.com/event/4th-targeted-protein-degradation-summit/
LOCATION:Digital Event\, EDT
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211026
DTEND;VALUE=DATE:20211029
DTSTAMP:20260515T211708
CREATED:20210622T141849Z
LAST-MODIFIED:20210622T141849Z
UID:30663-1635206400-1635465599@www.pharmajournalist.com
SUMMARY:5th Complement-based Drug Development Summit
DESCRIPTION:Discover the Intricacies of Complement Pathways to Accelerate Clinical Validation & Maximize Complement-Targeting in the Pan-Disease Setting \nBuilt with Alexion\, Apellis and Annexon\, the 5th Complement-based Drug Development Summit returns for its fifth year as the definitive industry dedicated forum to maximize complement-targeting in the pan-disease setting. \nWith pivotal clinical readouts poised to be released in 2021\, this year’s summit will once again unite thought leaders in complement-based drug development. \n \nExpect to be involved in interactive discussions on: \n\nHow dysregulated complement signaling contributes to disease and how to identify novel drug targets up and downstream of C3 and C5\nPreclinical and clinical pipeline progress of diverse drug modalities\, including gene therapy approaches\, small molecule inhibitors\, antibodies\, protease inhibitors\, nucleic acids & more!\nLeveraging complement proteins in precision-based medicine as disease biomarkers and companion diagnostics\nAddressing clinical challenges of complement-targeted therapeutic sequencing\, combinations and timing of administration\nExpanding the clinical utility of complement inhibitors across rare diseases\, as well as autoimmune\, ophthalmic\, neurological and cancer settings\n\nNew for this year\, you’ll have a two-tracked agenda with more speakers\, more content and more networking opportunities than ever before! As the growth potential of novel complement-targeting therapeutics becomes apparent\, join the conversation to realize the clinical and commercial potential of complement proteins as pan-disease targets! \nTo know more about 5th Complement-based Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/5th-complement-based-drug-development-summit/
LOCATION:Virtual/Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211026
DTEND;VALUE=DATE:20211029
DTSTAMP:20260515T211708
CREATED:20210701T113342Z
LAST-MODIFIED:20210701T113448Z
UID:30764-1635206400-1635465599@www.pharmajournalist.com
SUMMARY:6th Annual Neoantigen Based Therapies US Summit 2021
DESCRIPTION:Your Comprehensive End-to-End Guide to Transforming the Clinical Development of Cell & Vaccine Based Neoantigen Therapies \nThe growth and comeback of the neoantigen space has resulted in an abundance of new data\, innovative insights and valuable lessons learned on how to drive meaningful clinical responses\, all of which will be shared at the 6th Neoantigen Based Therapies US Summit. \nExploring the potential of shared neoantigens vs. personalized neoantigens and optimizing the selection and identification of the best and most immunogenic neoantigens\, the world’s leaders from the likes for BioNTech\, Gritstone\, Advaxis\, Genocea\, Treos Bio and many more will gather at the only 3-day summit focused on the exploding field of Neoantigen based Therapies. \nJoin over 100 experts to discuss what the optimal control\, clinical and combination trial designs should look like\, advances in accurate and robust validation assays\, and explore how we can manufacture effectively and at scale both shared and personalized neoantigen based therapies. \nLeave this meeting equipped with new collaborations across pharma\, biotech and academia\, and learn how to supercharge vaccine and cell immunotherapies for solid tumors and beyond. \nTo know more about 6th Annual Neoantigen Based Therapies US Summit 2021 please click here.
URL:https://www.pharmajournalist.com/event/6th-annual-neoantigen-based-therapies-us-summit-2021/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211026
DTEND;VALUE=DATE:20211029
DTSTAMP:20260515T211708
CREATED:20210715T092520Z
LAST-MODIFIED:20210715T092520Z
UID:30937-1635206400-1635465599@www.pharmajournalist.com
SUMMARY:2nd Supply Chain and Logistics for Cell Therapies Summit
DESCRIPTION:At the virtual 2nd Supply Chain and Logistics for Cell Therapies Summit\, your community will gather to network\, share exclusive insights in case-study led sessions\, and propose best practice for seamless vein-to-vein delivery at the clinical and commercial scale. \nImplement robust\, patient-centric supply chains for clinical to commercial readiness: \n\nBuild your supply strategyand manage risk and forecasting at scale by designing for growth\nMaximize your cloud-based and integrated systems and hear the latest innovations in chain of identity\n\nManage materials\, external manufacturing and facility design\n\nOptimize patient care with best practice guidelines and integrated platforms: \n\nUnderstand clinical requirementsand develop clinical strategies for seamless therapeutic delivery\nDiscuss and establish industry best practices and understand which standard practices can apply across a range of cell modalities\n\nMaintain product quality at scale for seamless delivery of autologous and allogeneic therapies: \n\nOptimize front-end processes and develop patient care organisations\nDiscuss quality control and site audits to ensure best standard of care and product quality\n\nFind out more >>> https://ter.li/mt5mh1
URL:https://www.pharmajournalist.com/event/2nd-supply-chain-and-logistics-for-cell-therapies-summit/
LOCATION:Virtual Event | Eastern Time
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211026
DTEND;VALUE=DATE:20211029
DTSTAMP:20260515T211708
CREATED:20210809T145746Z
LAST-MODIFIED:20210809T145746Z
UID:31270-1635206400-1635465599@www.pharmajournalist.com
SUMMARY:9th Advanced RWE Applications in Pharma
DESCRIPTION:Real-world evidence is at the root of an ongoing and critical transformation in medical care. By incorporating data from the real world into their development programs\, drug developers can now improve their clinical trial success by identifying and retaining suitable patients through increased patient stratification. \nThese are exciting times to reunite at the 9th Advanced Real-World Evidence Applications in Pharma to discuss the efforts to advance real-world evidence’s effective generation and utilization. \nThe stage is set for a collaborative discussion platform bringing together you and other stakeholders from functions across clinical development\, RWE\, RWD\, Data Science\, Regulatory Affairs\, Medical Affairs\, HEOR\, and many more! \nJoin us in October to overcome critical challenges in generating and implementing real-world evidence to enhance clinical R&D\, support regulatory submission and decision-making\, and ultimately drive commercial success. \nClick here to download the event guide for the full agenda\n\nWhat’s New in 2021? \n2020 was an exciting year for real-world data (RWD) and real-world evidence (RWE) experts within pharma and biotech. The FDA’s high-profile acceptance of RWD as part of their review for COVID-19 treatments and vaccines for emergency use authorization was a big moment for the industry. This is now energizing RWD and RWE into R&D and clinical activities – expediting novel treatments for patients and substantially reducing drug developers’ R&D spend. \nHowever\, major questions still need answers urgently. The 9th Advanced Real-World Evidence Applications in Pharma will return in October 2021 to delve into the core industry challenges\, including: \n\nAssessing the global regulatory environment for future RWE application\nAdvanced data acquisition and analytics to enable your R&D and clinically informed decision making\nLeverage RWE in your clinical activities – from patient selection to synthetic trial arm\nHow to create a robust\, regulatory-compliant RWE framework and data package for your successful IND filing\nMaximizing your product lifecycle through a comprehensive observational data program\nEstablishing pre-competitive collaboration to deepen your understanding of diseases\, offering patients a personalized and effective treatment through RWE & RWD\n\nBook now to save up to $750
URL:https://www.pharmajournalist.com/event/9th-advanced-rwe-applications-in-pharma/
LOCATION:Virtual
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211027
DTEND;VALUE=DATE:20211029
DTSTAMP:20260515T211708
CREATED:20200618T111721Z
LAST-MODIFIED:20210729T114826Z
UID:25936-1635292800-1635465599@www.pharmajournalist.com
SUMMARY:Protein Engineering Global USA
DESCRIPTION:The series brings together a global audience and global lineup of biocatalyst and protein modifications specialists to share how to implement the new technologies. With the applications growing across pharmaceutical\, flavour & fragrance\, consumer goods\, food & beverage and agrochemical sectors\, we have created a protein and enzyme engineering platform that will allow the community to improve capabilities to industrialize sustainable enzyme products and increase product efficiency globally. \nUnderstand the challenges and requirements of the industry in their internal R&D projects to support scale-up processes\, next-generation mutant library screening\, or knowledge of machine learning and AI to optimize biocatalysts for industrial applications. \nExpand your commercial opportunities and market growth by learning what new industry sectors are seeing the benefit of enzyme engineering to synthesize unprecedented molecules of interest and engage and network with these industries to form new third-party collaborations\, allowing you to advance your market growth. \nDemonstrate advancements in your service capabilities by actively promoting the work of your technical teams through bespoke webinar opportunities\, presentations\, and interactive discussion with the industry. \nWe are delighted to be hosting Protein Engineering Global 2 miles from San Jose International Airport SJC\, and offer a special bedroom rate to the attendees of the Protein Engineering Congress: \n$199 + tax per room per night – Please call +1 408-453-6200 and quote Kisaco research/Protein Engineering. \nDownload agenda: www.proteinengineeringglobal.com/
URL:https://www.pharmajournalist.com/event/protein-engineering-congress/
LOCATION:Holiday inn San Jose- Silicon Valley\, 1350 North 1st Street\, San Jose\, CA\, 95112\, United States
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211101
DTEND;VALUE=DATE:20211104
DTSTAMP:20260515T211708
CREATED:20210720T100504Z
LAST-MODIFIED:20210720T100504Z
UID:31015-1635724800-1635983999@www.pharmajournalist.com
SUMMARY:5th Antifibrotic Drug Development Summit - AFDD
DESCRIPTION:The 5th Antifibrotic Drug Development Summit will provide a unique opportunity to gain cross-discipline actionable insights into how the latest scientific research is being applied to fibrosis pipeline progress. Network with industry pioneers in hot areas of drug development\, specifically IPF\, NASH\, scleroderma\, IBD\, ILD\, CKD\, and more to apply disease-specific lessons agnostically\, and understand how the industry can achieve the crowning glory of pan-fibrosis antifibrotic drugs. \nUnmissable Highlights for 2021:  \n\nJoin the active discussion surrounding redefining approvable clinical endpoints with the FDA to enhance opportunities for creative clinical trial design and drive your clinical development\nEngage with early initiatives to establish clinical development programs in IBD-associated fibrosis with Cleveland Clinic to kickstart your intestinal fibrosis pipeline as this grows in interest for biopharma\nInvestigate the buzz around reprogramming epithelial cells to promote tissue repair in fibrotic disorders with Genentech to understand new strategies for regenerative medicine and overcome mechanistic bottlenecks\nGain vital insights from Pfizer on how the industry can revolutionize the translatability of current disease models and collaboratively guide the creation of technologies that can better mimic human physiology\nEmbrace more successful clinical trial design with an enhanced focus on patient-reported outcomes with Novartis to identify precision medicine approaches\, promote patient engagement\, and discuss regulatory barriers to novel endpoints\n\nHear from 35+ industry heavyweights including Genentech\, AstraZeneca\, FDA\, GSK\, Boehringer Ingelheim\, Pfizer\, Takeda\, and more to understand transformative mechanistic strategies for promoting tissue regeneration and repair\, discover more robust predictive models to improve translatability; and assess emerging non-invasive biomarkers that identify early signs of efficacy and drive successful clinical trials. \nTo know more visit: https://ter.li/afddpjel
URL:https://www.pharmajournalist.com/event/5th-antifibrotic-drug-development-summit-afdd/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211102
DTEND;VALUE=DATE:20211105
DTSTAMP:20260515T211708
CREATED:20210823T081823Z
LAST-MODIFIED:20210823T081930Z
UID:31388-1635811200-1636070399@www.pharmajournalist.com
SUMMARY:Gastrointestinal Cancer Drug Development Summit
DESCRIPTION:The Gastrointestinal Cancer Drug Development Summit is the only biopharma-led conference dedicated to identifying and progressing therapeutic opportunities in targeted and immunotherapies\, ADCs\, and precision oncology to address the large unmet clinical need in GI cancers. \n**This meeting is free-to-attend for drug developers\, research institutions\, and not-for-profit organizations**. \nRegister free to attend here: https://ter.li/t83wdr    \nThis industry-dedicated meeting offers a comprehensive insight into developing optimal clinical programs for targeted\, immune\, and ADC therapies in these solid tumors. Join us and our 39+ expert speaker faculty as we navigate cancer heterogeneity and develop biomarker-driven enrichment strategies to direct better treatments to specific patient subsets and invest in rationale therapeutic combination approaches for this vastly unmet clinical need. \nWhether your group is targeting microsatellite instable (MSI) and stable (MSS) CRC\, a rare GI malignancy or treatment-resistant HCC\, this unique forum is your opportunity to establish clinical collaborations\, plan new combinatorial studies and assess how a future drug candidate can change the clinical landscape. \nExplore the full conference guide here: https://ter.li/9m9m8u \n**A “drug developer” or “researcher” must have a pipeline candidate and/or work for an academic institution\, and must not provide solutions or services for a fee to any other company. All bookings under the drug developer/researcher category are subject to organizer approval.
URL:https://www.pharmajournalist.com/event/gastrointestinal-cancer-drug-development-summit/
LOCATION:Digital Event | EST
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211103
DTEND;VALUE=DATE:20211105
DTSTAMP:20260515T211708
CREATED:20210813T151459Z
LAST-MODIFIED:20210813T151459Z
UID:31349-1635897600-1636070399@www.pharmajournalist.com
SUMMARY:2nd Applied Biocatalysis Summit
DESCRIPTION:Understanding the most recent developments in enzyme-catalyzed processes\, computational technologies\, and cutting-edge methodologies in biocatalytic cascade reactions is key to help the API and chemical industries apply biocatalysis more effectively. \nSpecifically designed alongside experts in the field\, this conference will delve into the key technology\, enzyme design\, manufacturing\, and scale-up challenges that must be overcome to achieve the commercial promise of biocatalysis. \nJoin us online for 2 days of insightful content\, live Q&As\, and 2+ hours of networking\, as we bring together medication developers\, chemical manufacturers\, agriculturists\, and researchers working on the complex and difficult development of biocatalyst technology. \nThis is your comprehensive virtual guide to defining your commercial potential of implementing biocatalysis methods in 2021. \nTo know more visit: https://ter.li/s09i3k
URL:https://www.pharmajournalist.com/event/2nd-applied-biocatalysis-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211108
DTEND;VALUE=DATE:20211111
DTSTAMP:20260515T211708
CREATED:20210902T200827Z
LAST-MODIFIED:20210902T200827Z
UID:31541-1636329600-1636588799@www.pharmajournalist.com
SUMMARY:LEAP TA Life Sciences
DESCRIPTION:LEAP TA: Life Sciences is a unique open platform for the boldest talent leaders in the industry to engage in genuinely disruptive dialogues. Meet 80+ of your peers to rethink your recruitment approach\, allowing you to find better people faster in an increasingly competitive talent market. \nTaking part in this live online event will help you redefine your processes in an uncertain world\, and successfully navigate the new normal operating environment. \nThis is your opportunity to fill the gap between reading an article and hiring an external consultant to help you solve your own recruitment challenges for the short\, medium\, and long term. \nTo know more visit: https://ter.li/od0sc4
URL:https://www.pharmajournalist.com/event/leap-ta-life-sciences/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211109
DTEND;VALUE=DATE:20211111
DTSTAMP:20260515T211708
CREATED:20210820T074956Z
LAST-MODIFIED:20210820T074956Z
UID:31376-1636416000-1636588799@www.pharmajournalist.com
SUMMARY:Biomarkers for Rare Diseases Summit
DESCRIPTION:As reports predict the global biomarker test market will exceed $16bn in coming years\, the ability to identify and utilize predictive\, diagnostic and prognostic biomarkers is a priority for drug developers. In rare disease\, affecting over 400 million worldwide and where clinical insights exist for only around 400 of the 7000+ disease identified\, biomarkers are a valuable tool to accelerate drug development where there is current great unmet need. With this\, we are excited to announce the launch of the inaugural Biomarkers for Rare Diseases Summit. \n \nUniting world leaders developing novel therapeutics for rare disease\, we will discuss learnings\, challenges and future directions at the only summit dedicated to approaches to identify\, test and proof clinical biomarkers in rare disease for regulatory approval. From identifying disease driving biomarkers\, robust assay validation\, harnessing latest technologies and demonstrating therapy efficacy\, we bring you the definitive platform to accelerate bench to bedside rare disease development towards regulatory filing and patient populations. \nTo Know more visit: https://bit.ly/3AX0FIt
URL:https://www.pharmajournalist.com/event/biomarkers-for-rare-diseases-summit/
LOCATION:Digital
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211115
DTEND;VALUE=DATE:20211117
DTSTAMP:20260515T211708
CREATED:20210608T113322Z
LAST-MODIFIED:20210608T113525Z
UID:30480-1636934400-1637107199@www.pharmajournalist.com
SUMMARY:Medical Devices and IVD conference 2021
DESCRIPTION:Navigating new legislations and strategies to comply with regulatory requirements \nSMi is proud to announce the launch of their Medical Devices and IVD conference to be held in London in November 2021. \nThe MDR and IVDR updates will have a profound impact on the medical device industry\, bringing certain products into regulatory scope that were previously excluded\, introducing new manufacturing requirements\, and increasing the burden for post-market surveillance. What does this mean for the future of the Medical Devices and IVD industry? \nSMi’s inaugural Medical Devices and IVD conference will provide insight into the latest updates in EU MDR and IVDR regulations and will discuss strategies for how to best comply with these new regulations. In addition\, the conference will examine MHRA Guidance on Post-Brexit IVD Regulations and consider the evolving regulatory landscape for digital health software. Join Europe’s leading Medical Device and IVD Conference which will address post-market surveillance and vigilance\, clinical evaluations and investigations\, medical device regulatory affairs in global markets\, and much more. \n \nBENEFITS OF ATTENDING: \n\nEngage with notified body and competent authority representatives addressing key MDR and IVDR requirements\nGain insights from pharma regulatory experts in compliance and companion diagnostics\nUnderstand the latest guidance on Post-Brexit IVD Regulations to overcome common challenges\, in addition to considering evolving global regulations\nExamine post-market expectations for surveillance and vigilance of your medical devices\nDelve into how COVID-19 has impacted the MDR and IVD regulations\n\nView the full agenda and speaker line-up online: www.medicaldevices-ivd.com/pjwl \nPlus\, post-conference workshop will be taking place on 17th November in London: \nImplementing the EU MDR and Article 117\, An Industry Perspective \nWorkshop Leader: Blake Green\, Senior Manager Regulatory Affairs\, Amgen \nEARLY-BIRD RATES: \n\nBOOK BY 30TH JUNE AND SAVE £200\nBOOK BY 30TH SEPTEMBER AND SAVE £100\n\nRegistrations can be made on the event website at: www.medicaldevices-ivd.com/pjwl \nCHAIR FOR 2021: \nAndreas Stange\, Vice President\, TÜV SÜD \nHEAR FROM EXPERT INDUSTRY SPEAKERS: \n\nJessica Wilkerson\, Cyber Policy Advisor\, FDA\nSusan Neadle\, Executive Director\, Combination Products\, Devices\, Diagnostics & Digital Health Regulatory Affairs\, Amgen\nClaudia Dollins\, Head\, Precision Medicine & Companion Diagnostics\, Bristol Myers Squibb\nMichael Benecky\, Senior Director\, Global Regulatory Affairs\, UCB Biosciences\nChristophe Driesmans\, Head of the Materiovigilance Entity\, Federal Agency for Medicines and Health Products (FAMHP)\nMelanie Donguy\, Head Regulatory Affairs EMEA\, Bayer Radiology\nMarc Moal\, Head of Product Delivery & Project Management\, Merck Connected Health & Devices\nJim Leamon\, Director of Biologics Device Development\, Jazz Pharmaceuticals\nLouise Place\, Director\, Devices\, GlaxoSmithkline\nStefan Strasser\, Head of Department\, Austrian Medicines and Medical Devices Agency
URL:https://www.pharmajournalist.com/event/medical-devices-and-ivd-conference-2021/
LOCATION:London\, UK | Virtual Attendance Option Available
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211116
DTEND;VALUE=DATE:20211119
DTSTAMP:20260515T211708
CREATED:20210809T105337Z
LAST-MODIFIED:20210809T105337Z
UID:31259-1637020800-1637279999@www.pharmajournalist.com
SUMMARY:5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases
DESCRIPTION:In the unprecedented array\, and steady stream of novel\, topical\, and systemic agents entering various phases of drug development\, for critical inflammatory and autoimmune dermatological conditions this year\, the 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases\, returns to Boston for 2021. As the world’s leading\, and only forum committed to overcoming significant R&D hurdles\, and sharing of best practices for advancing efficacious next generation therapies for chronic inflammatory skin conditions\, this forum is not to be missed. \nWith the rising demand for consolidation and precision medicine\, along with multiple new agents edging closer to market for Atopic Dermatitis towards the end of the year\, the 5th annual meeting addresses advances and challenges in genetic discoveries\, antibody drug development\, delivery strategies and predictive and diagnostic technologies when developing safe and effective drugs for moderate-to-severe\, inflammatory skin conditions. \nEnsure you join this year’s 150+ expert community\, in-person\, to uncover recent studies evaluating critical inflammatory and auto-immune pathways\, gain a deeper understanding of promising biologics targeting IL-13\, IL-31\, IL-33\, whilst continuing to assess emerging efficacious targeted approaches when developing safer treatments to patients with debilitating skin diseases. Additionally\, obtain clarity on novel clinically validated endpoints within the regulatory landscape for critical dermatological conditions with high unmet need such as Hidradenitis Suppurativa and Vitiligo. \nLeave this year’s meeting having overcome innovative modelling challenges by gaining simulation tools/strategies to support your clinical drug development pipeline\, evaluate optimal dose and dosing regimen to support formulation changes for your approach\, whilst having debated what makes a dermatology investment most successful when advancing therapies for inflammatory and autoimmune skin conditions to market. \nTo find out more visit: https://ter.li/e93ads
URL:https://www.pharmajournalist.com/event/5th-annual-dermatology-drug-development-summit-for-inflammatory-skin-diseases/
LOCATION:Hilton Boston/Woburn\, 2 Forbes Rd\, Woburn\, MA\, 01801\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211116
DTEND;VALUE=DATE:20211119
DTSTAMP:20260515T211708
CREATED:20210812T114547Z
LAST-MODIFIED:20210812T114547Z
UID:31287-1637020800-1637279999@www.pharmajournalist.com
SUMMARY:3rd Inflammasome Therapeutics Summit
DESCRIPTION:Discover the Intricacies of Inflammasome Regulation\, Leverage Inflammasome Proteins as Biomarkers & Accelerate Novel Inflammasome Therapeutics into Proof-Of-Concept Clinical Trials & Beyond \nBuilt with Ventus Therapeutics\, Inflammasome Therapeutics\, Merck & more\, the Inflammasome Therapeutics Summit returns for its third year as the only industry-dedicated forum to discover the intricacies of inflammasome regulation and accelerate novel inflammasome therapeutics into proof of-concept clinical trials and beyond! \nWith a plethora of inflammasome-targeted drugs poised to enter the clinic in 2021\, this year’s summit will once again unite thought leaders in inflammasome drug development. \nExpect to be involved in interactive discussions on: \n\nHow dysregulated inflammasome activation\, formation and signaling contributes to disease and how to identify novel drug targets beyond NLRP3\nThe interface of inflammasome signaling with innate immunity\, microbial interactions\, metabolism\, neuroimmune and other systems\nLeveraging inflammasome proteins in precision-based medicine as disease biomarkers and companion diagnostics in both the preclinical and clinical setting\nIdentifying and translating the most promising therapeutic applications of inflammasome-targeted drugs across monogenic diseases\, as well as infectious\, ophthalmic\, neurological and cancer settings\n\nThis year’s meeting has two parallel tracks of learning with 30+ speakers sharing highly anticipated case studies. As the growth potential of novel inflammasome therapeutics becomes apparent\, join the conversation to validate novel inflammasome targets beyond NLRP3 and realize the clinical and commercial potential of inflammasome proteins across different diseases! \nTo Know more visit: https://ter.li/bdw0tf
URL:https://www.pharmajournalist.com/event/3rd-inflammasome-therapeutics-summit/
LOCATION:Virtual/Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211116
DTEND;VALUE=DATE:20211119
DTSTAMP:20260515T211708
CREATED:20210903T051305Z
LAST-MODIFIED:20210903T051305Z
UID:31548-1637020800-1637279999@www.pharmajournalist.com
SUMMARY:3rd Exosome Based Therapeutic Development Summit
DESCRIPTION:The 3rd Exosome-Based Therapeutic Development Summit returns with a more comprehensive agenda than ever before\, reuniting leading pharma\, biotech\, technology providers and academic teams to advance therapeutically relevant exosome-based therapeutics in regenerative medicine\, autoimmunity\, COVID-19 and beyond. \nDeep diving into the key challenges such as sourcing\, characterization\, cargo loading\, manufacturing and clinical development\, this year’s summit will be your comprehensive roadmap to realizing\, strategizing and advancing the full therapeutics and drug delivery opportunities offered by exosomes. \nTailor-made to showcase the latest innovations and interactively discuss the industry’s most important talking points\, join leading biopharmaceutical Directors\, VPs and C-Level Executives to successfully optimize\, accelerate and scale your exosome-based therapeutics as next generation drugs for unmet clinical needs \nKey Highlights: \n\nShining a spotlight on orally delivered bacterial extracellular vesicles with unique pharmacological profiles with striking anti-inflammatory effects\, an exciting new approach for exosome therapeutics with Evelo Biosciences\n\n\nDeep dive into the latest data coming out of the clinic with key learnings from phase I/II trials of Covid-19\, oesteoarthirtus and gastrointestinal diseases with insights from Organicell\, University of Athens & University of Louisville\n\n\nNavigating the complex regulatory landscape for exosomes to understand what the FDA requires to progress through each development stage and the potential for successful applications into 2021 with insights from Rion\n\n\nExploring proteomic insights in understanding EVs and the mechanisms of action of EV-mediated RNA delivery to enable more efficient and efficacious exosome therapies with Exogenus Therapeutics Aruna Bio\, Stem XO & Baker Heart and Diabetes Institute\n\n\nExpanding the boundaries of engineering exosomes including cell selection\, applications of the technology\, monitoring biodistribution and enabling direct delivery with Exogenus VivaZome Therapeutics\, OmniSpriant & Exogenus Therapeutics\n\nTo know more visit: https://ter.li/h99vsb
URL:https://www.pharmajournalist.com/event/3rd-exosome-based-therapeutic-development-summit/
LOCATION:Digital Event\, EST
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211117
DTEND;VALUE=DATE:20211119
DTSTAMP:20260515T211708
CREATED:20210628T103640Z
LAST-MODIFIED:20210628T103640Z
UID:30747-1637107200-1637279999@www.pharmajournalist.com
SUMMARY:Wnt & β-Catenin Targeted Drug Discovery Summit
DESCRIPTION:The Wnt & β-Catenin Targeted Drug Discovery Summit is the only meeting uniting leading pharma\, pioneering biotechs and reputed academics under a mutual and ambitious objective of accelerating your novel Wnt/β-catenin candidates into clinic and market. \nBuilt with Leap Therapeutics\, Fog Pharma\, Surrozen\, Iterion Therapeutics\, Genentech\, and other leading companies\, the summit will allow you to gain knowledge on the inhibition and activation of the Wnt pathway. You can be sure to take away practical insights and actionable strategies on how to harness this previously undruggable target. \nWith 24+ expert speakers\, this is your definitive opportunity to be a part of this exciting and growing community\, and this dedicated virtual summit will ensure you get your answers to your questions. \nTo find out more and view the 2021 speaker line-up\, download the full event guide. \n \n5 unmissable keynotes include: \n\nSupercharging Your Wnt/β-catenin Clinical Program by Surrozen\, Iterion Therapeutics\, AntlarA & Leap Therapeutics\nGetting a Grip on Wnt Biology to Theorize the Latest Opportunities & Understandings with Iterion Therapeutics\, Genentech & Auburn University\nOpportunities to Aid Drug Discovery & Further Research Efforts with Biovista & the DTRF\nDelving into Immuno-Oncology to Further Oncological Treatment Efficacy\, brought to you by UAB\, Duke Cancer Institute & Shandong First Medical University\nHarnessing Novel Pathways Approach to Drive Preclinical Insights delivered by\nFog Pharma\, RedX Pharma & The University of Oxford\n\nTo know more about the Wnt & β-Catenin Targeted Drug Discovery Summit please click here.
URL:https://www.pharmajournalist.com/event/wnt-%ce%b2-catenin-targeted-drug-discovery-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR